Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Physicians Becoming Picky about Generic Brands: Survey
March 19, 2015
- Chuikyo OKs Quantitative Premium Calculation for Operating Profit Rates
March 19, 2015
- Japan to Build Dementia Patients Registration System: WHO Ministerial Conference
March 19, 2015
- Chuikyo Approves Reimbursement for RAS Gene Test Kit; Listing Scheduled for April
March 19, 2015
- Chuikyo Approves Listing of ViiV Healthcare’s HIV Treatment Triumeq; Listing Scheduled for March 25
March 19, 2015
- MHLW to Urge Insurers to Promote Generic Use among Beneficiaries of High-Cost Healthcare Benefit System
March 18, 2015
- Govt Panel Members Push Deregulation of Bungyo Rules
March 16, 2015
- Govt Denies Intentional Falsification of Data in J-ADNI Study
March 16, 2015
- Prime Minister Abe Indicates the Need to Promote the Use of Biosimilars
March 16, 2015
- 70 Institutions Picked to Treat Post-HPV Vaccine Adverse Reactions
March 13, 2015
- PMDA Plans to Introduce Full Scale “Patient ADR Reporting System” by FY2018
March 13, 2015
- PMDA Adopts FY2015 Project Plan Calling for Sped-Up Review
March 12, 2015
- Japan Generic Share Little over 50% If In-House Prescriptions Included: Official
March 11, 2015
- Mandatory CDISC-Based Submissions to Begin in October 2016
March 11, 2015
- Panel OKs 44 More Diseases as Designated Intractable Diseases
March 10, 2015
- MHLW to Target 75% Generic Share for Welfare Recipients
March 10, 2015
- MHLW’s Panel on Orphan Cancer Holds First Meeting; Draft Report Expected This Summer
March 10, 2015
- Editor’s Pick: Five Healthcare News Headlines for Feb. 23 - March 8
March 9, 2015
- New Dosage Added to Taxol for Gastric Cancer Treatment
March 9, 2015
- Gilead’s Sofosbuvir Likely to Get Japan Greenlight as Early as March-End
March 6, 2015
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…